BridgeBio Oncology Therapeutics
BBOT | NASDAQ
$1.98
-$0.16 (-7.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.01
+$0.03 (+1.52%)
After-hours:
Nov 16, 2026, 7:00 PM ET
-7.48%
(1D)Rating
25.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #923/1021 (Top 90%)
Key Statistics
Market Data
Market Cap $158.9M
1D Range
1.98 2.23
52W Range
1.98 13.73
Valuation (TTM)
PE 0
PB 0.54
EV/EBITDA 0.18
Valuation (NTM)
Forward PE N/A
Forward PEG 0.00
Price Target $20.00
Cash Flow
FCF Yield -95.0%
SBC Adj. FCF Yield -104.4%
SBC Impact -9.9%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -59.4% |
N/A
FCF 3Y | 5Y -52.3% |
N/A
Returns
ROA -49.5%
ROE -49.0%
ROIC -63.3%
Financial Health
Net Cash
$193.87M
Current Ratio 4.08
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinosit...
Sector Healthcare
Industry Biotechnology
Employees 88
IPO Date Aug 12, 2025
Website bbotx.com
Fiscal Year January - December
Latest News
10 months ago · seekingalpha.com
BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 TranscriptBridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
Analyst Summary
# of Analysts
10
Consensus
Buy
Price Target
$20.00
Upside
+910.10%
Buy (10)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove BBOT